DJIA 17,689.86 -56.12 -0.32%
NASDAQ 5,128.28 -0.50 -0.01%
S&P 500 2,103.84 -4.79 -0.23%
market minute promo

Alkermes, Inc. (NASDAQ: ALKS)

70.02 2.49 (3.69%)

Quote as of


company name or ticker

Recent Quotes

ALKS $70.02 3.69%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $68.52
Previous Close $67.53
Daily Range $67.76 - $70.71
52-Week Range $38.49 - $75.17
Market Cap $10.4B
P/E Ratio -114.46
Dividend (Yield) $0.00 (0.0%)
Volume 749,107
Average Daily Volume 966,857
Current FY EPS -$1.02

Sector

Healthcare

Industry

Drug Makers

Alkermes, Inc. (ALKS) Description

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Website: http://www.alkermes.com/

News & Commentary

Why I Think Alkermes Could Be a Top Performing Stock Ahead of 2016

Upcoming catalysts including new drugs for schizophrenia and depression could send Alkermes shares soaring.

Alkermes' Reports Wider Q2 Loss, Increases Guidance - Analyst Blog

Premarket Biotech Digest: Amgen Beats, GlaxoSmithKline Corruption Charges, VTv Therapeutics Flops On

Premarket Biotech Digest: Amgen Beats, GlaxoSmithKline Corruption Charges, VTv Therapeutics Flops On Debut

Alkermes' (ALKS) CEO Richard Pops on Q2 2015 Results - Earnings Call Transcript

Alkermes (ALKS) Q2 2015 Results - Earnings Call Webcast

Will McKesson (MCK) Keep the Earnings Streak Alive? - Analyst Blog

Will Express Scripts (ESRX) Miss Earnings Estimates in Q2? - Analyst Blog

Xenoport Not Getting Much Love Ahead Of Key Data

Midyear Report Card: Grading My Biotech Predictions for 2015

One Foolish investor shines a bright light on his biotech stocks predictions for this year.

5 Big Upcoming FDA Decisions Expected in July

See More ALKS News...

ALKS's Top Competitors

ALKS $70.02 (3.69%)
Current stock: ALKS
AMGN $176.59 (2.85%)
Current stock: AMGN
GILD $117.86 (-0.03%)
Current stock: GILD
BIIB $318.78 (0.56%)
Current stock: BIIB